Yunsong Yu
Overview
Explore the profile of Yunsong Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
341
Citations
4823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao L, Pu J, Liu Y, Cai H, Han M, Yu Y, et al.
Front Microbiol
. 2025 Mar;
16:1543509.
PMID: 40078538
Carbapenem-resistant (CRPA) has become a serious global health concern due to the limited treatment options. The primary resistance mechanism in CRPA involves the production of metallo-β-lactamases (MBLs), making MBL-producing a...
2.
Yuan J, Guo F, Li A, Xu N, Chang X, Xiao Z, et al.
J Glob Antimicrob Resist
. 2025 Mar;
PMID: 40064443
Background: Ceftazidime-avibactam was approved in patients with hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), based on the multinational Phase 3 REPROVE study. This study assessed efficacy and safety of ceftazidime-avibactam...
3.
Yu Z, Hu H, Liu X, Liu J, Yu L, Wei A, et al.
Antimicrob Agents Chemother
. 2025 Mar;
:e0185924.
PMID: 40047414
Polymyxin B, a last resort for carbapenem-resistant gram-negative bacteria (CRGNB) infections, has infection site-specific pharmacokinetic/pharmacodynamic (PK/PD) properties. However, there is little clinical evidence to support optimal exposures of polymyxin B...
4.
Jiang J, Wang L, Hu Y, Chen X, Li P, Zhang J, et al.
EBioMedicine
. 2025 Mar;
113:105627.
PMID: 40024096
Background: Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKp) has been increasingly reported worldwide, posing a severe challenge to public health; however, the mechanisms driving its emergence and global dissemination remain unclear. Methods:...
5.
Chen M, Jiang S, Sun L, Wang H, Di L, Liu Y, et al.
Int J Antimicrob Agents
. 2025 Feb;
:107469.
PMID: 39986399
Objectives: This study aimed to investigate the "seesaw effect" of daptomycin (DAP) and ceftobiprole (BPR) on DAP-resistant (DAP-R) methicillin-resistant Staphylococcus aureus (MRSA) isolates. Methods: Broth microdilution minimum inhibitory concentrations (MICs)...
6.
Sun L, Zhu F, Chen Y, Shi Y, Wang H, Yu Y, et al.
BMC Infect Dis
. 2025 Feb;
25(1):208.
PMID: 39939973
Background: Methicillin resistant Staphylococcus aureus (MRSA) is one of the main causes of hospital-acquired infections, but the diagnosis of MRSA pseudomembranous enteritis has faded in recent years. Here, we reported...
7.
Wang H, Wang G, Gao Y, Qu L, Wang H, Deng M, et al.
Clin Microbiol Infect
. 2025 Feb;
PMID: 39938681
No abstract available.
8.
Wang Y, Wang H, Zhang Y, Ma A, Liu D, Li X, et al.
Nat Med
. 2025 Jan;
PMID: 39891005
No abstract available.
9.
Zhou L, Yao J, Zhang Y, Zhang X, Hu Y, Liu H, et al.
NPJ Antimicrob Resist
. 2025 Jan;
3(1):3.
PMID: 39843962
Ceftazidime-avibactam (CZA) is currently one of the last resorts used to treat infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. However, KPC variants have become the main mechanism mediating CZA...
10.
Fu Y, Morris F, Pereira S, Kostoulias X, Jiang Y, Vidor C, et al.
J Glob Antimicrob Resist
. 2025 Jan;
41:189-194.
PMID: 39826686
Objective: The IMP-4 carbapenemase is an endemic cause of carbapenem resistance in the Asia-Pacific region. Our aim was to determine the dissemination mechanism of the bla gene. Methods: Twelve representative...